MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China
MacroGenics Contacts: Jim Karrels, Senior Vice President, CFO Anna Krassowska, Ph.D., Vice President, Investor Relations & Corporate Communications 1-301-251-5172, info@macrogenics.com I-Mab Biopharma Contacts: Jielun Zhu, CFO jielun.zhu@i-mabbiopharma.comAmanda Dai, Associate Director of Public Relation zhenhua.dai@i-mabbiopharma.comWeimin Tang, EVP and Head of Global Business Development Weimin.tang@i-mabbiopharma.comSource: MacroGenics, Inc.